2026 Eric Jonasch: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	72	19839	18606	9883	9108	538	18585

Overview

Eric Jonasch is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans multiple areas within medicine and biochemistry, genetics, and molecular biology, with a notable focus on cancer-related studies. Their work incorporates clinical and molecular aspects related to cancer treatment and biology.

The scientist's research is situated primarily within these main fields of study:

Medicine
Biochemistry, Genetics and Molecular Biology

Within these disciplines, they have contributed extensively to subfields including:

Pulmonary and Respiratory Medicine
Molecular Biology
Cancer Research
Oncology
Surgery

Eric Jonasch's published work addresses several core topics such as:

Renal cell carcinoma treatment
Renal and related cancers
Cancer Genomics and Diagnostics
Cancer, Hypoxia, and Metabolism
Cancer Immunotherapy and Biomarkers
Bladder and Urothelial Cancer Treatments
Pancreatic and Hepatic Oncology Research

Their recent published papers include:

Clear cell renal cell carcinoma ontogeny and mechanisms of lethality, 2020, Nature Reviews Nephrology
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types, 2021, Annals of Oncology
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages, 2021, Cell
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis, 2021, Nature Medicine
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network

Eric Jonasch frequently collaborates with other researchers, notably:

Nizar M. Tannir
Pavlos Msaouel
Matthew T. Campbell
Amishi Y. Shah
José A. Karam

The scientist has published numerous articles in several key journals, including:

Journal of Clinical Oncology
Annals of Oncology
The Oncologist
Journal of the National Comprehensive Cancer Network
Clinical Cancer Research

Best Publications

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

8488
Citations
Comprehensivemolecular characterization of clear cell renal cell carcinoma

Chad J. Creighton;Margaret Morgan;Preethi H. Gunaratne;Preethi H. Gunaratne;David A. Wheeler

4161
Citations
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

895
Citations
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

DJ McGrail;PG Pilié;NU Rashid;L Voorwerk

768
Citations
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

Eric Jonasch;Frank G. Haluska

718
Citations
Renal cell carcinoma

Eric Jonasch;Jianjun Gao;W Kimryn Rathmell

650
Citations
NCCN clinical practice guidelines in oncology: kidney cancer.

Robert J Motzer;Neeraj Agarwal;Clair Beard;Graeme B Bolger

633
Citations
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Robert J Motzer;Eric Jonasch;Neeraj Agarwal;Sam Bhayani

533
Citations
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Eric Jonasch;Cheryl Lyn Walker;W. Kimryn Rathmell

411
Citations
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Lijun Zhou;Xian-De Liu;Mianen Sun;Xuesong Zhang

385
Citations
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

351
Citations
The PI3K/AKT Pathway and Renal Cell Carcinoma

Huifang Guo;Peter German;Shanshan Bai;Sean Barnes

333
Citations
Featured Updates to the NCCN Guidelines

Robert J. Motzer;Eric Jonasch;M. Dror Michaelson;Lakshminarayanan Nandagopal

319
Citations
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline

Sherri M. Donat;Mireya Diaz;Jay Todd Bishoff;Jonathan A. Coleman

308
Citations
Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines

Robert J. Motzer;Eric Jonasch;Neeraj Agarwal;Clair Beard

294
Citations
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

287
Citations
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Brian I Rini;Bohuslav Melichar;Takeshi Ueda;Viktor Grünwald

267
Citations
Dual Chromatin and Cytoskeletal Remodeling by SETD2.

In Young Park;Reid T. Powell;Durga Nand Tripathi;Ruhee Dere

242
Citations
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

Eric Jonasch;Frede Donskov;Othon Iliopoulos;W Kimryn Rathmell

214
Citations
Kidney cancer, version 1.2021: Featured updates to the nccn guidelines

Robert J. Motzer;Eric Jonasch;Shawna Boyle;Maria I. Carlo

198
Citations

Frequent Co-Authors

Nizar M. Tannir The University of Texas MD Anderson Cancer Center

Christopher G. Wood The University of Texas MD Anderson Cancer Center

Surena F. Matin The University of Texas MD Anderson Cancer Center

Pheroze Tamboli The University of Texas MD Anderson Cancer Center

Gordon B. Mills Oregon Health & Science University

Toni K. Choueiri Harvard University

Brian I. Rini Vanderbilt University Medical Center

Cheryl L. Walker Baylor College of Medicine

Robert J. Motzer Memorial Sloan Kettering Cancer Center

Elizabeth R. Plimack Fox Chase Cancer Center

External Links

Personal website of Eric Jonasch

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Exploring related healthcare fields can provide valuable pathways for those interested in a medical career or seeking flexible study options. For example, adn nursing programs (Associate Degree in Nursing) are an accessible way to begin a nursing career quickly, and may have lower entry barriers compared to traditional MD programs.

Many students are also interested in healthcare roles that don’t require direct patient care. Accredited medical billing and coding schools that accept fafsa offer online programs with financial aid, opening the door to administrative roles in the healthcare system.

If test anxiety is a concern, some nursing schools that don’t require teas or hesi make it easier for applicants by eliminating entrance exam requirements, streamlining the admissions process.

For those seeking fast-track leadership roles, a health administration degree can be completed online in an accelerated format, preparing graduates for management careers in hospitals, clinics, and healthcare organizations.